Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI

Trial Profile

Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2012

At a glance

  • Drugs Abciximab (Primary) ; Reteplase (Primary)
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms GUSTO-V; GUSTOsex
  • Most Recent Events

    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top